Babak Boroojerdi Selected Research

rotigotine

1/2019	Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study.
3/2016	The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis.
1/2016	Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
1/2015	Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.
12/2014	Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.
3/2014	Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study.
1/2014	Associations between severity of motor function and nonmotor symptoms in Parkinson's disease: a post hoc analysis of the RECOVER Study.
9/2013	The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease.
7/2013	Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER.
1/2013	Treatment of patients with early and advanced Parkinson's disease with rotigotine transdermal system: age-relationship to safety and tolerability.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Babak Boroojerdi Research Topics

Disease

29	Parkinson Disease (Parkinson's Disease) 01/2021 - 05/2005
5	Dyskinesias (Dyskinesia) 03/2016 - 06/2012
3	Disease Progression 01/2021 - 08/2019
3	Pain (Aches) 03/2014 - 08/2003
2	Stroke (Strokes) 12/2003 - 08/2002
1	Demyelinating Diseases (Demyelinating Disease) 01/2022
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2022
1	Neuromyelitis Optica (Devic's Disease) 01/2022
1	Multiple Sclerosis 01/2022
1	Restless Legs Syndrome (Restless Legs) 07/2017
1	Sleepiness 07/2013
1	Sleep Initiation and Maintenance Disorders (Insomnia) 07/2013
1	Hallucinations (Hallucination) 07/2013
1	Nausea 01/2011
1	Dizziness (Lightheadedness) 01/2011
1	Paresis (Hemiparesis) 12/2007
1	Dystonic Disorders (Writer's Cramp) 12/2003
1	Phantom Limb (Phantom Limbs) 08/2003

Drug/Important Bio-Agent (IBA)

23	rotigotine FDA Link 01/2019 - 05/2005
7	Dopamine Agonists (Dopamine Agonist)IBA 07/2017 - 05/2005
5	Levodopa (L Dopa)FDA LinkGeneric 03/2016 - 06/2007
3	ropinirole (Requip)FDA LinkGeneric 08/2011 - 09/2007
2	Phosphotransferases (Kinase)IBA 01/2021 - 01/2020
2	Leucine (L-Leucine)FDA Link 01/2021 - 01/2020
2	Pharmaceutical PreparationsIBA 01/2020 - 06/2007
2	Pramipexole (Mirapex)FDA LinkGeneric 09/2007 - 06/2007
1	Immunoglobulin G (IgG)IBA 01/2022
1	Fc Receptors (Fc Receptor)IBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	Myelin-Oligodendrocyte GlycoproteinIBA 01/2022
1	Luxol Fast Blue MBS (Luxol fast blue)IBA 01/2022
1	amsonic acid (DAS)IBA 07/2017
1	Monoamine Oxidase (MAO)IBA 01/2016
1	Selegiline (E250)FDA LinkGeneric 01/2016
1	Dopamine Agents (Dopaminergic Agents)IBA 07/2013
1	Cabergoline FDA LinkGeneric 09/2007
1	Botulinum Toxins (Botulinum Toxin)IBA 12/2003

Therapy/Procedure

5	Transdermal Patch 03/2016 - 05/2005
3	Transcranial Magnetic Stimulation 12/2003 - 08/2003
2	Wearable Electronic Devices 01/2019 - 01/2017
1	Therapeutics 08/2019
1	Perioperative Period 07/2010
1	Lasers (Laser) 12/2007
1	Activities of Daily Living (ADL) 05/2007
1	Conduction Anesthesia (Regional Anesthesia) 08/2002